[1] Pollicino T, Caminiti G. HBV-integration studies in the clinic: role in the natural history of infection[J]. Viruses, 2021, 13(3):368.
[2] Tang L S Y, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review[J]. JAMA, 2018, 319(17): 1802-1813.
[3] 陈文雅,赵红,谢雯.免疫抑制疗法相关的HBV再激活及其预防[J].肝脏,2023,28(03):275-278.
[4] Yoo S, Lee D, Shim J H, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment[J]. Clin Gastroenterol Hepatol, 2022, 20(4): 898-907.
[5] Shi Y, Zheng M. Hepatitis B virus persistence and reactivation[J]. BMJ, 2020, 370:m2200.
[6] Papatheodoridi M, Tampaki M, Lok A S, et al. Risk of HBV reactivation during therapies for HCC: a systematic review[J]. Hepatology, 2022, 75(5): 1257-1274.
[7] Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, et al. HBV reactivation in rheumatic diseases patients under therapy: a meta-analysis[J]. Microb Pathog, 2018, 114:436-443.
[8] Shah R, Ho E Y, Kramer J R, et al. Hepatitis B virus screening and reactivation in a national VA cohort of patients with inflammatory bowel disease treated with tumor necrosis factor antagonists[J]. Dig Dis Sci, 2018, 63(6): 1551-1557.
[9] Varfolomeev E, Vucic D. Intracellular regulation of TNF activity in health and disease[J]. Cytokine, 2018, 101:26-32.
[10] Moelants E A, Mortier A, Van Damme J, et al. Regulation of TNF-alpha with a focus on rheumatoid arthritis[J]. Immunol Cell Biol, 2013, 91(6): 393-401.
[11] Huang K, Chu N, Ding Y, et al. Comparative pharmacokinetics, safety, and immunogenicity study of the prefilled syringe and lyophilized formulation of a recombinant human tumor necrosis factor-alpha receptor II:lgG Fc fusion protein in Healthy Chinese Male Subjects[J]. Clin Pharmacol Drug Dev, 2022, 11(9): 1116-1123.
[12] Liu L N, Wang G, Hendricks K, et al. Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models[J]. Stem Cells Transl Med, 2013, 2(5): 362-375.
[13] Lau G, Yu M L, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy[J]. Hepatol Int, 2021, 15(5): 1031-1048.
[14] 于乐成,侯金林.2017年欧洲肝病学会临床实践指南:HBV感染的管理(精粹)[J].临床肝胆病杂志,2017,33(6):1017-1032.
[15] Hwang J P, Feld J J, Hammond S P, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update[J]. J Clin Oncol, 2020, 38(31): 3698-3715. |
